DE69309052T2 - Oral anzuwendende suspension bestehend aus stabilisiertem rockenpulver eines hydratisierten cephalosporins - Google Patents

Oral anzuwendende suspension bestehend aus stabilisiertem rockenpulver eines hydratisierten cephalosporins

Info

Publication number
DE69309052T2
DE69309052T2 DE69309052T DE69309052T DE69309052T2 DE 69309052 T2 DE69309052 T2 DE 69309052T2 DE 69309052 T DE69309052 T DE 69309052T DE 69309052 T DE69309052 T DE 69309052T DE 69309052 T2 DE69309052 T2 DE 69309052T2
Authority
DE
Germany
Prior art keywords
pct
hydrated
oral suspension
cephalosporine
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69309052T
Other languages
English (en)
Other versions
DE69309052D1 (de
Inventor
Donald Johnson
Lorraine Wearley
Rebecca Galeos
Joel Sequeira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69309052D1 publication Critical patent/DE69309052D1/de
Publication of DE69309052T2 publication Critical patent/DE69309052T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE69309052T 1992-04-30 1993-04-30 Oral anzuwendende suspension bestehend aus stabilisiertem rockenpulver eines hydratisierten cephalosporins Expired - Lifetime DE69309052T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87688192A 1992-04-30 1992-04-30
PCT/US1993/003856 WO1993021923A1 (en) 1992-04-30 1993-04-30 Stable hydrated cephalosporin dry powder for oral suspension formulation

Publications (2)

Publication Number Publication Date
DE69309052D1 DE69309052D1 (de) 1997-04-24
DE69309052T2 true DE69309052T2 (de) 1997-06-19

Family

ID=25368763

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309052T Expired - Lifetime DE69309052T2 (de) 1992-04-30 1993-04-30 Oral anzuwendende suspension bestehend aus stabilisiertem rockenpulver eines hydratisierten cephalosporins

Country Status (23)

Country Link
US (1) US5599557A (de)
EP (1) EP0642344B1 (de)
JP (1) JP3378004B2 (de)
KR (1) KR100257803B1 (de)
AT (1) ATE150310T1 (de)
AU (1) AU674516B2 (de)
CA (1) CA2134467A1 (de)
CZ (1) CZ283428B6 (de)
DE (1) DE69309052T2 (de)
DK (1) DK0642344T3 (de)
EE (1) EE03039B1 (de)
ES (1) ES2099438T3 (de)
FI (1) FI945081A0 (de)
GR (1) GR3023516T3 (de)
HK (1) HK1002407A1 (de)
HU (1) HU215958B (de)
NO (1) NO307594B1 (de)
NZ (1) NZ252433A (de)
PL (1) PL171630B1 (de)
RU (1) RU2123863C1 (de)
SK (1) SK279329B6 (de)
UA (1) UA27899C2 (de)
WO (1) WO1993021923A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
EP2172223B1 (de) * 2007-06-22 2020-12-16 Kaneka Corporation Eine physiologisch wirksame substanz enthaltende zusammensetzung
US20110123505A1 (en) * 2007-08-22 2011-05-26 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
WO2011139253A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
RU2550932C1 (ru) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Способ получения нанокапсул цефалоспориновых антибиотиков в ксантановой камеди

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4803082A (en) * 1987-10-28 1989-02-07 Warner-Lambert Company Flavor and sweetness enhancement delivery systems and method of preparation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation

Also Published As

Publication number Publication date
CA2134467A1 (en) 1993-11-11
KR950701224A (ko) 1995-03-23
US5599557A (en) 1997-02-04
EP0642344A1 (de) 1995-03-15
KR100257803B1 (en) 2000-08-01
JP3378004B2 (ja) 2003-02-17
UA27899C2 (uk) 2000-10-16
HUT71226A (en) 1995-11-28
NO944113D0 (no) 1994-10-28
PL171630B1 (pl) 1997-05-30
RU2123863C1 (ru) 1998-12-27
WO1993021923A1 (en) 1993-11-11
SK279329B6 (sk) 1998-10-07
JPH07506366A (ja) 1995-07-13
RU94046038A (ru) 1996-11-10
CZ263694A3 (en) 1995-04-12
AU4115293A (en) 1993-11-29
EP0642344B1 (de) 1997-03-19
GR3023516T3 (en) 1997-08-29
ATE150310T1 (de) 1997-04-15
FI945081A (fi) 1994-10-28
CZ283428B6 (cs) 1998-04-15
ES2099438T3 (es) 1997-05-16
AU674516B2 (en) 1997-01-02
NO307594B1 (no) 2000-05-02
NO944113L (no) 1994-10-28
EE03039B1 (et) 1997-10-15
DE69309052D1 (de) 1997-04-24
SK131194A3 (en) 1995-07-11
HU9403108D0 (en) 1995-02-28
NZ252433A (en) 1996-07-26
FI945081A0 (fi) 1994-10-28
HK1002407A1 (en) 1998-08-21
DK0642344T3 (da) 1997-07-07
HU215958B (hu) 1999-03-29

Similar Documents

Publication Publication Date Title
DE69309052T2 (de) Oral anzuwendende suspension bestehend aus stabilisiertem rockenpulver eines hydratisierten cephalosporins
HU9400430D0 (en) New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
GR1002907B (el) Επικαλυμμενο δισκιο μηλεινικης τριμεβουτινης
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
DE3474024D1 (en) Contraceptive compositions based on esters of levo-norgestrel
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
HU9302813D0 (en) Pharmaceutical compositions containing new benzimidazole derivatives and process for preparing the active ingredients
KR950007828A (ko) 구강 위생 개선용 조성물
AU565187B2 (en) 2-n-cycloalkylmethyl-3-oxo-5,6-diaryl-as-triazines
DE2961713D1 (en) Organic diamine compounds for use as oral hypoglycemic agents and pharmaceutical compositions thereof
HUT42099A (en) Process for preparing 2,3-diamino-2,3-dideoxy-hexose derivatives and pharmaceutical compositions containing thereof as active substances
IL67400A0 (en) 3,7alpha-diazacyclohepta(j,k)fluorene derivatives,their preparation and pharmaceutical compositions containing them
HUT61776A (en) Process for producing 3' and/or 4' oh-modificated elsamycin derivatives and pharmaceutical compositions containing them as active components
EP0080600A3 (en) Use of 2-hydroxy-3,4,4-trimethyl-cyclopent-2-ene-1-one as odorant ingredient
IL64839A (en) N-arylmethyl-4-(methylanilino)-5-sulfamoyl-anthranilic acids,a process for their preparation and pharmaceutical compositions containing them
IL64641A (en) 4-aminoalkyl-1,3-dihydro 2(2h)-indolone derivatives,process for their preparation and pharmaceutical compositions containing them
SG25394G (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition